key: cord-0947473-ws4xyvol authors: Xu, Hai; Martin, Angel; Singh, Avneet; Narasimhan, Mangala; Lau, Joe; Weinberg, Mitchell; Jauhar, Rajiv; Rao, Gaurav title: Pulmonary embolism in patients hospitalized with COVID-19 (From a New York health system) date: 2020-07-24 journal: Am J Cardiol DOI: 10.1016/j.amjcard.2020.07.036 sha: 960dfb985bb95c958379fcb0f6fb7daa7b70a1de doc_id: 947473 cord_uid: ws4xyvol Pulmonary Embolisms (PEs) in coronavirus disease 2019 (COVID-19) have increasingly been reported in observational studies. However, limited information describing their clinical characteristics and outcomes exists. Our study aims to describe clinical features and risk stratification strategies of hospitalized COVID-19 patients with PE. We retrospectively analyzed 101 hospitalized patients with COVID-19 infection and acute PE. Clinical outcomes measured were intensive care unit (ICU) admission, mechanical ventilation, bleeding and transfusion events, acute kidney injury (AKI) and mortality. Pulmonary Severity Index (PESI) scores were used for risk stratification. The most common comorbidities were hypertension (50%), obesity (27%) and hyperlipidemia (32%) among this cohort. Baseline D-dimer abnormalities (4647.0 ± 8281.8) were noted on admission with a 3-fold increase at the time of PE diagnosis (13288.4 ± 14917.9; p<0.05). 5 (5%) patients required systemic thrombolysis and 12 (12%) patients experienced moderate to severe bleeding. 31 (31%) patients developed AKI and 1 (1%) patient required renal replacement therapy. 23 (23%) patients were admitted to ICU, of which 20 (20%) patients received mechanical ventilation. The mortality rate was 20%. Most patients (65%) had Intermediate to high risk PESI scores (>85), which portended a worse prognosis with higher mortality rate and length of stay. In conclusion, this study provides characteristics and early outcomes for hospitalized patients with COVID-19 and acute pulmonary embolism. PESI scores were utilized for risk stratifying clinical outcomes. Our results should serve to alert the medical community to heighted vigilance of this VTE complication associated with COVID-19 infection. The novel 2019 coronavirus disease has led to a global pandemic with a spectrum of clinical manifestations among infected patients 1 . Cardiopulmonary injury related to this viral infection is now recognized as a common feature resulting in high mortality 2 . Prior cardiovascular comorbidities, such as obesity, diabetes, hypertension, and coronary artery disease (CAD), portend a poor prognosis amongst these patients 3 . An association of COVID-19 infection with venous thromboembolic events (VTEs) has increasingly been recognized by observational studies outside the United States (US) 4, 5 . This was further corroborated by high incidences of VTE findings, such as clinically overlooked pulmonary embolism, on autopsy 6 . COVID-19 creates a hypercoagulable milieu due to exaggerated inflammatory response and, thus, leads to a coagulation disarray, as evidenced by elevated inflammatory markers including D-dimer [7] [8] [9] . However, such a correlation has not been systemically studied or published to date. We present our experience, including demographics, clinical characteristics, and outcomes, in COVID-19 patients who also developed confirmed pulmonary embolisms during the course of their initial COVID-19 illness. Hospital, two tertiary medical centers within the Northwell Health system. Both A total of 101 patients were included in this study ( Figure 1 ). Basic demographics including mean age, gender and ethnicity distributions are presented in Table 1 . The most common comorbidities were hypertension, obesity, hyperlipidemia, diabetes mellitus, smoking history and previous VTE, which was similar to the larger Northwell experience 10 Average time from hospital admission to PE diagnosis was 5 days (± 6.1). At the time of PE diagnosis, tachycardia, hypotension, hypoxia and fever were most frequently reported physical exam findings (Table 2) . EKG rhythm at time of PE diagnosis was most commonly sinus tachycardia followed by atrial fibrillation or atrial flutter. The McGinn-White sign of S1Q3T3 pattern was observed in 9 patients (9%) 13 . RV strain on CT was noted in approximately half of this cohort with an estimated mean pulmonary artery systolic pressure (PASP) of 37.1 mmHg. Based on imaging findings, vital signs and biomarker measurements, 75 patients (75%) were diagnosed with sub-massive PE and 3 patients (3%) were diagnosed with massive PE. At the final study follow-up date, all 101 patient (100%) received full dose anticoagulation therapy (Table 3) . Twenty-three patients (23%) were admitted to ICU, with 20 To our knowledge, this cohort represents the largest collection of COVID-19 patients with concurrent pulmonary embolism. As reported in prior COVID-19 studies, our patients were more likely to have cardiovascular disease risk factors such as hypertension, hyperlipidemia, obesity, diabetes mellitus, and smoking history 14 . Only a small percentage of our patients had previous VTEs or malignancies. Direct effects of COVID-19 or its sequela, via severe inflammatory response and hypoxia, are postulated to be the main drivers of pulmonary thrombotic events in our patients 15, 16 . Compared to the larger Northwell series 10 , our cohort had higher rates of ICU admission, mechanical ventilation, AKI and mortality, suggesting the addition of pulmonary embolism to COVID-19 exacerbates morbidity and mortality. Additionally, the majority of this cohort had PESI scores >85, which has previously been shown to predict higher short-term adverse events and mortality 17 . When we applied such risk predictor to this COVID-19 population, high risk patients required significantly more ICU level care, increased LOS in the hospital, and experienced a higher mortality rate. To our knowledge, our study is the first to suggest that high PESI scores represent a poor prognostic indicator in COVID-19 patients who develop acute PE. We report an overall low incidence of DVT and ischemic stroke in our studied population, although diagnostic testing was limited in an effort to minimize personnel exposure and viral transmission. This observation may suggest that localized in situ pulmonary thrombosis, rather than embolism, occurs among these COVID-19 patients. Most patients (75%) in this cohort were categorized as having sub-massive PE, with either positive cardiac biomarkers or RV dysfunction on imaging. It has been shown that COVID-19 and its sequela of ARDS managed with high positive end expiratory pressure can exert detrimental effects on the myocardium and right ventricular function 25 . It is also worth noting these findings predict adverse short-and long-term outcomes in the PE population 26 . Given the high rate of sub-massive PE in our cohort, we emphasize the importance of increased clinical awareness, as well as early imaging testing for expeditely diagnosing PE in COVID-19 patients. All patients require therapeutic anticoagulation, when PE diagnosis is highly suspected based on clinical context, D-dimer values, and imaging results, with escalation to potential thrombolytic therapy when indicated clinically. Based on this practice strategy, we report an overall small number of bleeding events in our group. Understanding the potential adverse effects of severe hemorrhage and mortality associated, the benefits of anticoagulation should still be balanced with bleeding risks on an individual basis Our study is limited by its inherent retrospective nature. Only patients who were stable enough to undergo CTA were analyzed, resulting in unavoidable selection bias. Similarly, patients with acute kidney injury, which commonly co-exists in COVID-19, were excluded in an effort to prevent contrast nephropathy. In an attempt to curtail viral transmission, many of these patients underwent alternative diagnostic testing such as point of care ultrasound to evaluate right ventricle dilatation or dysfunction. Such testing results are frequently ambiguous and difficult to capture for our cohort. For all the aforementioned reasons, PE was likely underestimated in our institutional dataset. In conclusion, acute pulmonary embolism is increasingly being recognized as a complication of active COVID-19 infection. Our results suggest the use of PESI scores and Ddimer measurements for risk stratification and management guidance in this patient population. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Bilateral patchy opacity (X-ray) 53 (52%) White blood cell (10 9 /L) 9.5 (± 4. China medical treatment expert group for clinical characteristics of coronavirus disease 2019 in China Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-Infected Pneumonia in Wuhan, China COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Routine electrocardiography in screening for pulmonary embolism Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) COVID-19 and the cardiovascular system COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up Does the pulmonary embolism severity index accurately identify low risk patients eligible for outpatient treatment Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 Hlh Across Speciality Collaboration UK. COVID-19: consider cytokine storm syndromes and immunosuppression COVID-19 and its implications for thrombosis and anticoagulation Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19 Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association We would like to acknowledge the Northwell COVID-19 Research Consortium for their support and resources. * Values are presented as no (%) or mean (± standard deviation) where applicable. † Transthoracic studies performed in 41 patients. Calculated percentages for right and left ventricular dysfunction, as well as Ejection fraction was based on this number of patients. Pulmonary arterial systolic pressure was only able to be estimated on 29 patients as tricuspid regurgitation velocity envelope were not well visualized in the other cases.